Divi's Laboratories Limited
Incorporated in 1990, Divis Laboratories Ltd manufactures and exports API's, Intermediates and Nutraceutical ingredients
What Divi's files
- Others53
- Investor Meet24
- Board Meeting9
- Important9
- Dividend/Bonus4
- Results1
Divi's Laboratories' board proposed a ₹30/share dividend for FY26. This payout is subject to shareholder approval and income tax withholding. Investors must submit tax documents by the cutoff date for accurate TDS rate application.
Divi's Laboratories has updated its internal policy for determining and disclosing material company information. This move aims to streamline how important developments are identified and communicated to the stock exchanges, increasing transparency for investors. The company has also clarified the roles of key management personnel in both assessing materiality and...
Divi's Laboratories has announced a board meeting to approve the financial results for the quarter and half-year. The Board has proposed a robust dividend of ₹30 per share (1,500% on a ₹2 face value) for FY 2024-25, pending shareholder approval. Investors should update bank details to ensure smooth electronic dividend...
Divi's Laboratories has announced a long-term international manufacturing and supply agreement with a global pharma company to produce advanced intermediates. The partnership will see a capacity expansion costing Rs. 650-750 Cr, funded through phased advances from the customer. This deal secures assured supply for the client and strengthens Divi’s position...
Divi's Laboratories reported consolidated revenue of ₹9,712 Cr for FY25, up 18.7% YoY, with PBT and PAT rising to ₹2,916 Cr and ₹2,191 Cr respectively. Standalone revenue stood at ₹9,550 Cr with PAT of ₹2,209 Cr. Commercial operations began at Unit III greenfield project near Kakinada, capitalizing ₹755 Cr. The...